DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)

Date: February 11, 2021

Time: 12:00 PM to 4:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Trinh T. Tran, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-5843
trinh.tran@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed)

Date: February 17, 2021
Time: 1:00 PM to 4:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Gerald L. McLaughlin, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-5819
gm145a@nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)

Date: February 18, 2021

Time: 12:00 PM to 3:00 PM

Agenda: To review and evaluate grant applications

Place: National Institutes of Health
National Institute on Drug Abuse
301 North Stonestreet Avenue
Bethesda, MD 20892
(Virtual Meeting)

Contact Person: Ipolia R. Ramadan, Ph.D.
Scientific Review Officer
Office of Extramural Policy and Review
Division of Extramural Research
National Institute on Drug Abuse, NIH
301 North Stonestreet Avenue, MSC 6021
Bethesda, MD 20892
(301) 827-4471
ramadanir@mail.nih.gov

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel NIDA Centers Review

Date: February 26 - March 1, 2021

Time: 10:00 AM to 5:30 PM
Agenda: To review and evaluate grant applications

Place: National Institutes of Health  
National Institute on Drug Abuse  
301 North Stonestreet Avenue  
Bethesda, MD 20892  
(Virtual Meeting)

Contact Person: Ipolia R Ramadan, Ph.D.  
Scientific Review Officer  
Office of Extramural Policy and Review  
Division of Extramural Research  
National Institute on Drug Abuse, NIH  
301 North Stonestreet Avenue, MSC 6021  
Bethesda, MD 20892  
(301) 827-4471  
ramadanir@mail.nih.gov


Dated: January 8, 2021.

Tyeshia M. Roberson,

Program Analyst,

Office of Federal Advisory Committee Policy.

[FR Doc. 2021-00574 Filed: 1/13/2021 8:45 am; Publication Date: 1/14/2021]